Does the iFuse Procedure Work?

Peter Whang, MD

This presentation was recorded during the 4th SI Joint Surgery Society Meeting (iFuse Surgeon User Group). Peter Whang, MD is a paid consultant and clinical trial investigator for SI-BONE, Inc.
 
One or more of the individuals named herein may be past or present SI-BONE employees, consultants, investors, clinical trial investigators, or grant recipients. Research described herein may have been supported in whole or in part by SI-BONE.

Outline
• SI Joint Pathology – Burden of Disease
• Clinical Trials Overview – SIFI, InSIte, iMIA
• Clinical Evidence

The iFuse Implant System is intended for sacroiliac fusion for conditions including sacroiliac joint dysfunction that is a direct result of sacroiliac joint disruption and degenerative sacroiliitis. This includes conditions whose symptoms began during pregnancy or in the peripartum period and have persisted postpartum for more than 6 months. There are potential risks associated with the iFuse Implant System. It may not be appropriate for all patients and all patients may not benefit. For information about the risks, visit: www.si-bone.com/risks